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SUMMARY
The results of 14 years'experience in the surgical treatment ofmyastheniagravis
are reported. Twenty-one patients (14 female, 7 male) underwent thymectomy
for myasthenia gravis between 1971 and 1984. The mean age of the patients
was 33 years (range 14 -57 years). The median duration ofsymptoms prior to
surgery was 18 months (range 5 months to 35 years). The mean follow-up was
5.3 years. There were no post-operative deaths: 76% obtained benefit from
thymectomy. The patients' age, sex, duration ofsymptoms and histology ofthe
thymus gland did not correlate with the result oftreatment. This series suggests
that, while thymectomy is often beneficial in the treatment ofmyasthenia gravis,
there are no accurate predictors of the outcome following surgery.
INTRODUCTION
Myasthenia gravis is an uncommon disease characterised by a fluctuating
course and occasional spontaneous remissions. The association between this
disease and thymic pathology has long been recognised.1 Since the results of
thymectomies were first reported, over forty years ago,2 surgery has played an
increasingly important role in its management. While there is general agreement
about the potential benefits of operative intervention,3 there has been consider-
able debate about the indications for timing of surgery, and also the prediction of
its results. The high morbidity and mortality quoted in earlier series,2 4 together
with reports that young women with mild disease of short duration were more
likely to do better,5 tended to influence patient selection. As a result, a fair assess-
ment of thymectomy was not possible. More recent series have broadened
patient selection considerably,6 7 8 yet reported benefits have remained high.
Prediction of the outcome in the individual case remains an area of disagree-
ment.67 The purpose of this paper is to review our experience in the surgical
treatment of myasthenia gravis and to determine whether it is possible to predict
the results of treatment.
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PATIENTS
It has been the practice in the Neurology Department in this hospital to refer only
those patients with the generalised and bulbar forms ofthe disease. Traditionally,
those of sixty years of age or older, and those with the purely ocular forms of the
disease, have not been referred. In view of these selection criteria, we estimate
that approximately 80% of myasthenics in this hospital have come to surgery.
From November 1971 to February 1984, 21 patients (14 female, 7 male) with
myasthenia gravis were referred to the Department of Thoracic Surgery for
thymectomy. (Table 1). Prior to referral, the diagnosis had been established by a
consultant neurologist. The age of patients at the time ofsurgery ranged from 14
to 57 years (mean of 33 years). The mean age of the females was less than that
of the males: 29.2 and 41.1 years respectively. The duration of symptoms prior
to thymectomy ranged from 5 months to 35 years (median of 18 months).
Standard anti-cholinesterase therapy was continued up until the night before
surgery and recommenced immediately afterwards. All underwent a total
thymectomy via a median sternotomy. All patients have been assessed post-
operatively at regular intervals by a consultant neurologist. The period of review
following surgery ranged from 6 months to 12 years, with a mean of 5.3 years.
TABLE I
Patients who underwent thymectomy
Duration of Length of
Patient Age Sex symptoms Type of Histology of follow-up Outcome
(months) disease the thymus (months)
Di 24 M 24 Bulbar Hyperplasia 6 Moderate benefit
NE 57 M 6 General Normal 48 Considerable benefit
JK 22 F 48 General Hyperplasia 132 Considerable benefit
RC 48 M 12 Bulbar Thymoma 78 Moderate benefit
NK 25 F 10 General Hyperplasia 60 Considerable benefit
MC 57 F 420 General Normal 12 Moderate benefit
NB 42 M 26 General Normal 132 Moderate benefit
ID 27 F 72 General Hyperplasia 6 Considerable benefit
RD 36 M 10 General Thymoma 48 Considerable benefit
AG 18 F 11 General Hyperplasia 18 Considerable benefit
BO'H 14 F 5 General Hyperplasia 84 Considerable benefit
MF 16 F 10 General Hyperplasia 6 Moderate benefit
MB 23 F 18 General Normal 72 No benefit
OMcG 21 F 12 General Thymoma 48 No benefit
NMcM 41 F 21 General Normal 24 No benefit
JW 34 M 5 Bulbar Thymoma 108 No benefit
EC 47 M 18 Bulbar Thymoma 96 Worse
AF 53 F 14 Bulbar Thymoma 72 Remission
MH 18 F 30 General Normal 144 Remission
AG 29 F 60 General Normal 72 Remission





divided into four groups:
- patients in remission with no symptoms and no therapy.
- those who had obtained considerable benefit with only mild symptoms
remaining but still on some therapy.
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3 - those who had obtained moderate benefit with drug dosage of about half
the pre-operative amount.
4 - those who obtained no benefit or were worse off following surgery,
needing either the same or additional therapy.
Only 4 patients achieved complete remission (19%), all of whom were women.
Overall 16 (76%) benefited from thymectomy (Table II). There was no difference
in benefit between the sexes. Five achieved no benefit or were worse offfollowing
surgery (24%). There were no post-operative deaths or deaths at a later period.
Five of the group of 21 patients required ventilatory support for periods ranging
from 5 days to one month post-operatively.
TABLE II
Outcome following surgery
Group No. Per cent
1. Remission 4 19 )
2. Considerable benefit 7 33 > 76
3. Moderate benefit 5 24 )
4. No benefit or worse 5 24
The most common pathological findings were hyperplasia (7 cases), thymoma
(6 cases) and normal glands (8 cases). There appeared to be no correlation
between thymic pathology and the surgical result. There was no difference in age
between those who benefited from thymectomy and those who did not (mean
34.0 and 33.2 years respectively). There was no difference between the median
duration of symptoms (benefit 19 months, no benefit 18 months) or in the sex
distribution (benefit 79% female, 71 % male). (Table III).
TABLE III
Relationship of outcome to pre-operative details and histology
Median
Mean duration of
Group Sex age symptoms Type of Histology(2)
(years) (months) disease(M)
1. Remission 4F 36.3 45 2G, 2B 3N, 1T
2. Considerable benefit 5F, 2M 28.4 11 7G 1T, 1N, 5H
3. Moderate benefit 2F, 3M 37.4 24 3G, 2B 1T, 2N, 2H
4. No benefit or worse 3F, 2M 33.2 18 3G, 2B 2N, 3T
(1) G = generalised, B = bulbar.
(2) N = normal, T =thymoma, H = hyperplasia.
DISCUSSION
When Blalock reported the results of the first series of thymectomies for
myasthenia gravis 40 years ago, he concluded that, while the procedure was
probably beneficial, it was not possible to predict the outcome of surgery.2
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Since then, there has been unanimous agreement that thymectomy can be of
benefit but considerable disagreement on the prediction of results. Five years
after this first series, Keynes reported that a long history prior to surgery was
prejudicial to recovery.9 He also made the important observation that, due to the
fluctuating course of the disease, it was difficult to assess the results. In an
extensive review of Keynes's work, Simpson in 1958 reaffirmed the conclusion
that those most likely to benefit from surgery were those with symptoms of less
than five years' duration.' Apart from this, no other significant factors were
observed which could help predict the outcome.
While there are still those who feel that young women6, 11 and those patients
having a short history6 10 constitute favourable groupings, there is considerable
evidence from others that there are no reliable predictors ofa favourable result.3,7
Attempts have been made to correlate thymic pathology9 14 and acetylcholine
receptor antibody titres13 14 with the results of surgery. However, recent reports
suggest that, with the exception of thymomas which may indicate a poor
prognosis, pathological findings6 7 15, 16 and reduction in acetylcholine receptor
antibody titres"1 12,16 are not important factors in the outcome following
thymectomy.
From this series we can make several observations. With 76% obtaining benefit
from thymectomy there can be no doubt that it is a worthwhile procedure. There
was no sex difference between those who improved following surgery and those
who did not, but it is worth noting that all those who obtained a complete
remission were female. We could find no evidence that age or short duration of
symptoms were favourable factors, in fact one patient with symptoms for 35
years benefited from surgery. Neither did thfymic histology seem to correlate with
the eventual outcome, two patients with thymomas responding well to surgery.
That there is a very definite morbidity associated with thymectomy in those
suffering from myasthenia gravis'7 is borne out by five out of our group of 21
requiring post-operative ventilatory support. Unlike some of the earlier series
which reported a high mortality,2'4 we had no deaths in the immediate post-
operative period or later during the period of this review.
In conclusion we feel that thymectomy is a relatively safe and effective procedure
in the management of myasthenia gravis. From our experience there are no
factors which enable one to predict the outcome of surgery. For this reason we
feel that surgery should be offered to all except those with the mildest disease.
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